Autologous cell-based delivery ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 211 | Hypoplastic left heart syndrome | 1 |
211. Hypoplastic left heart syndrome
Clinical trials : 22 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 5 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01883076 (ClinicalTrials.gov) | May 15, 2013 | 11/6/2013 | Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome | Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome | Hypoplastic Left Heart Syndrome | Biological: autologous cell-based delivery | Timothy J Nelson, MD, PhD | University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospitals and Clinics of Minnesota;Children's Hospital Los Angeles;Children's Hospital Colorado;Mayo Clinic | Completed | N/A | 18 Months | All | 30 | Phase 1 | United States |